Industry Reports Tuesday, Mar 27, 2018

Intercept Pharmaceuticals Inc (ICPT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.


Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops and commercializes treatments for non-viral, progressive liver diseases. It develops products using its proprietary bile acid chemistry. The company’s lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor. The company owns worldwide rights to OCA except for China, Japan and Korea, where the rights were exclusively licensed to Sumitomo Dainippon Pharma Co., Ltd., (Sumitomo Dainippon) along with an option to exclusively license OCA in certain other Asian countries. The product is also under development for the treatment of various other liver diseases. Intercept’s other developmental products in pipeline include INT-767 for the treatment of fibrosis; and INT-777 for type 2 diabetes. Intercept is headquartered in New York, the US.

Intercept Pharmaceuticals Inc Key Recent Developments

Feb 14,2018: Intercept Pharmaceuticals Reports Net Sales Of $129.2 Million For The Year Ended December 31, 2017

Nov 27,2017: Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development

Jul 31,2017: Intercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update

Jun 22,2017: Intercept's primary biliary cholangitis treatment wins 2017 Premio Galeno Italia Chemical Synthesis Drug Award

May 19,2017: Intercept receives 2017 Industry Innovation Award from NORD for primary biliary cholangitis therapy